CJC-1295 (no DAC)

Mechanism

Modified GRF 1-29 (also called CJC-1295 without DAC or Mod GRF 1-29) is a synthetic analog of the first 29 amino acids of growth hormone-releasing hormone with four amino acid substitutions (Ala2, Gln8, Ala15, Leu27) that confer resistance to enzymatic degradation by dipeptidyl peptidase IV (DPP-IV). Without the DAC moiety, its half-life is approximately 30 minutes, producing a transient pulse of GH release from anterior pituitary somatotrophs. This short-acting profile better mimics the natural pulsatile pattern of GH secretion and is often combined with growth hormone-releasing peptides (GHRPs) for synergistic effects.

What the literature has looked at

• Studies have investigated pulsatile GH stimulation that mimics physiological secretion
• Research has examined synergistic effects when combined with GHRPs like ipamorelin
• Studies have explored body composition and recovery signaling pathways
• Pharmacokinetic studies have characterized the short-acting release profile

Research context, not a claim about what this compound does. Research Use Only — not for human or animal consumption. 21+.

Cited work

• Prakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs. 1999;12(2):139-157.

  Review of GHRH(1-29) analogs examining the pharmacology of pulsatile GHRH receptor activation for GH release, establishing the foundational receptor pharmacology shared by Mod GRF 1-29.

• Wilton P, et al. Pharmacokinetics of growth hormone-releasing hormone(1-29)-NH2 and stimulation of growth hormone secretion in healthy subjects after intravenous or intranasal administration. Acta Paediatr Suppl. 1993;388:10-15.

  Measured GHRH(1-29)-NH2 pharmacokinetics and the growth hormone response it produced in healthy subjects across two routes of administration.